X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4821) 4821
Publication (401) 401
Book Review (48) 48
Book Chapter (38) 38
Conference Proceeding (5) 5
Dissertation (5) 5
Book / eBook (4) 4
Magazine Article (2) 2
Web Resource (2) 2
Presentation (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3439) 3439
index medicus (2616) 2616
female (2125) 2125
male (2008) 2008
middle aged (1822) 1822
oncology (1811) 1811
radiotherapy (1630) 1630
aged (1618) 1618
adult (1437) 1437
concomitant (1267) 1267
treatment outcome (1104) 1104
chemotherapy (946) 946
cancer (927) 927
adjuvant temozolomide (829) 829
glioblastoma (761) 761
radiation-therapy (724) 724
surgery (717) 717
survival (656) 656
care and treatment (628) 628
combined modality therapy (610) 610
retrospective studies (608) 608
aged, 80 and over (579) 579
temozolomide (533) 533
therapy (526) 526
clinical neurology (505) 505
prognosis (501) 501
medicine & public health (482) 482
radiology, nuclear medicine & medical imaging (478) 478
rheumatology (432) 432
rheumatoid arthritis (428) 428
arthritis, rheumatoid - drug therapy (419) 419
glioblastoma multiforme (411) 411
analysis (407) 407
double-blind (406) 406
squamous-cell carcinoma (404) 404
research (378) 378
monoclonal-antibody (377) 377
pharmacology & pharmacy (366) 366
follow-up studies (365) 365
trial (360) 360
chemoradiotherapy (359) 359
concomitant chemoradiotherapy (353) 353
neoplasm staging (351) 351
antineoplastic combined chemotherapy protocols - therapeutic use (347) 347
radiation (347) 347
concomitant methotrexate (346) 346
survival rate (341) 341
radiation therapy (340) 340
antirheumatic agents - therapeutic use (339) 339
patients (338) 338
tumors (334) 334
dacarbazine - analogs & derivatives (332) 332
antitumor necrosis factor (331) 331
drug therapy, combination (326) 326
disease-free survival (323) 323
young adult (313) 313
cisplatin (310) 310
prospective studies (306) 306
survival analysis (305) 305
health aspects (303) 303
animals (299) 299
risk factors (297) 297
concomitant chemotherapy (290) 290
brain neoplasms - drug therapy (289) 289
brain neoplasms - pathology (283) 283
randomized-trial (281) 281
head and neck cancer (280) 280
gliomas (278) 278
adolescent (277) 277
receiving concomitant methotrexate (276) 276
adalimumab (273) 273
carcinoma (267) 267
head and neck neoplasms - radiotherapy (263) 263
malignant glioma (262) 262
drug therapy (261) 261
brain neoplasms - therapy (256) 256
etanercept (255) 255
infliximab (253) 253
radiotherapy dosage (253) 253
locally advanced head (251) 251
medicine, general & internal (249) 249
time factors (249) 249
carcinoma, squamous cell - radiotherapy (245) 245
cisplatin - administration & dosage (244) 244
clinical trials (241) 241
concomitant use (239) 239
glioma (237) 237
hematology, oncology and palliative medicine (236) 236
brain neoplasms - mortality (234) 234
glioblastoma - drug therapy (231) 231
glioblastoma - pathology (230) 230
head and neck neoplasms - drug therapy (230) 230
multiforme (227) 227
tumor necrosis factor-alpha - antagonists & inhibitors (223) 223
carcinoma, squamous cell - drug therapy (217) 217
glioblastoma - mortality (214) 214
glioblastoma - therapy (214) 214
brain neoplasms - radiotherapy (211) 211
dacarbazine - therapeutic use (211) 211
neurology (211) 211
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4605) 4605
French (110) 110
German (77) 77
Japanese (29) 29
Spanish (24) 24
Czech (13) 13
Russian (12) 12
Korean (8) 8
Polish (8) 8
Portuguese (6) 6
Italian (3) 3
Hungarian (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 14, pp. 1324 - 1334
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 916 - 926
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 11/2018, Volume 39, Issue 1, pp. 7 - 12
Thrombosis remains a major cause of morbidity and mortality. Consequently, advances in antithrombotic therapy are needed to reduce the disease burden... 
anticoagulants | mortality | thrombosis | morbidity | stroke | myocardial infarction | COAGULATION ACTIVATION | CONCOMITANT ASPIRIN | MYOCARDIAL-INFARCTION | THROMBUS FORMATION | PLUS ASPIRIN | SELECTIVE DEPLETION | ANTIPLATELET THERAPY | ATRIAL-FIBRILLATION | FACTOR XIA INHIBITOR | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ANTISENSE OLIGONUCLEOTIDES
Journal Article
Journal Article
Journal of Clinical Gastroenterology, ISSN 0192-0790, 03/2013, Volume 47, Issue 3, pp. 228 - 232
Journal Article
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 2, pp. 177 - 186.e3
Data are available such that choice of Helicobacter pylori therapy for an individual patient can be reliably predicted... 
Gastroenterology and Hepatology | Clarithromycin | Proton Pump Inhibitors | Review | Tetracycline | Treatment | Helicobacter pylori | Concomitant Therapy | Treatment Success | Amoxicillin | Quadruple Therapy | Bismuth | Metronidazole | Sequential Therapy | Evidence Based | Treatment success | Sequential therapy | Proton pump inhibitors | Concomitant therapy | Evidence based | Quadruple therapy | Therapy | PROTON-PUMP INHIBITOR | Sequential | CAGA STATUS | TRIPLE THERAPY | INFECTION | ANTIBIOTIC-RESISTANCE | RANDOMIZED-TRIAL | CONTAINING CONCOMITANT THERAPY | SEQUENTIAL THERAPY | ERADICATION THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Bismuth - administration & dosage | Helicobacter Infections - drug therapy | Humans | Metronidazole - administration & dosage | Treatment Failure | Clarithromycin - administration & dosage | Drug Resistance, Bacterial | Amoxicillin - administration & dosage | Drug Therapy, Combination | Evidence-Based Medicine | Anti-Bacterial Agents - administration & dosage | Urea | Medical colleges | Continuing medical education | Gastrointestinal diseases | Helicobacter infections | Evidence-based medicine | Antibacterial agents | treatment | concomitant therapy | amoxicillin | treatment success | clarithromycin | sequential therapy | proton pump inhibitors | review | tetracycline | metronidazole | quadruple therapy | evidence based | bismuth
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2019, Volume 31, Issue 10, pp. 1206 - 1210
BACKGROUNDConcomitant nonbismuth quadruple therapy is recommended as first-line treatment for Helicobacter pylori infection in high clarithromycin resistance areas, but the ideal duration of the regimen remains elusive... 
duration | CLARITHROMYCIN | treatment | Helicobacter pylori | CONSENSUS | REGIMEN | SEQUENTIAL THERAPY | ERADICATION | INFECTION | concomitant | GASTROENTEROLOGY & HEPATOLOGY | Usage | Clarithromycin | Pantoprazole | Patient outcomes | Amoxicillin | Helicobacter infections | Dosage and administration | Drug therapy, Combination | Drug therapy | Nitroimidazoles
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 84, Issue 5, pp. 1198 - 1205
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 709 - 722
In patients with glioblastoma, the addition of bevacizumab to radiotherapy and temozolomide induction therapy and the use of bevacizumab maintenance therapy did not influence overall survival... 
CONCOMITANT RADIOCHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | RECURRENT GLIOBLASTOMA | CLINICAL-TRIALS | MALIGNANT GLIOMAS | QUALITY-OF-LIFE | RESPONSE ASSESSMENT CRITERIA | MULTIFORME | HIGH-GRADE GLIOMA | ENDOTHELIAL GROWTH-FACTOR | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Induction Chemotherapy | Male | Glioblastoma - radiotherapy | Bevacizumab | Young Adult | Dacarbazine - analogs & derivatives | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Combined Modality Therapy | Brain Neoplasms - drug therapy | Disease-Free Survival | Quality of Life | Aged | Glioblastoma - drug therapy | Glioblastoma - mortality | Dosage and administration | Research | Temozolomide | Drug therapy, Combination | Drug therapy | Glioblastoma multiforme | Nuclear magnetic resonance--NMR | Intravenous administration | Glucocorticoids | Brain cancer | Body weight | Glioblastoma | Radiation therapy | Survival | Patients | Quality of life | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article